Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®

Drug Safety

Volumn 38, Issue 12, 2015, Pages 1179-1186

  Nguyen, Thi Thanh Loan ^a   Palmaro, Aurore ^a   Montastruc, François ^a,b   Lapeyre Mestre, Maryse ^a,b   Moulis, Guillaume ^a,b  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; ROMIPLOSTIM; BENZOIC ACID DERIVATIVE; FC RECEPTOR; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBRAL SINUS THROMBOSIS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS; AGING; AGONISTS; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGING; BENZOATES; HUMANS; HYDRAZINES; MYOCARDIAL INFARCTION; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RISK FACTORS; STROKE; THROMBOPOIETIN; THROMBOSIS;

EID: 84948586471     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0337-1     Document Type: Article

References (34)

1. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365:734–41.
2. ®. 2008. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed 30 Sept 2014.
3. ®. 2008. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed 30 Sept 2014.
4. European Medicines Agency. Committee for Medicinal Products for Human Use assessment report for Nplate. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000942/WC500039475.pdf. Accessed 30 Sept 2014.
5. European Medicines Agency. Committee for Medicinal Products for Human Use assessment report for Revolade. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001110/WC500089967.pdf. Accessed 30 Sept 2014.
6. US Food and Drug Administration Departement of Health and Human Services. Supplement approval for Promacta. 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed 30 Sept 2014.
7. ®. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001110/WC500152310.pdf. Accessed 30 Sept 2014.
8. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
9. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393–402.
10. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121:537–45.
11. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161:411–23.
12. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372–82.
13. Khellaf M, Michel M, Quittet P, Viallard J-F, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118:4338–45.
14. Garabet L, Lee S, Mowinckel M-C, Jonassen C, Liebman H, Bussel J, et al. Effect of thrombopoietin receptor agonists on coagulation and platelet activation in patients with immune thrombocytopenia. Haematologica. 2015;100:586.
15. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37:1030–7.
16. Khellaf M, Viallard J-F, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98:881–7.
17. González-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparrós I, Arratibel MC, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111–6.
18. Moulis G, Bagheri H, Sailler L, Jonville-Bera A-P, Weber E, Guy C, et al. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French pharmacovigilance assessment. Eur J Intern Med. 2014;25:777–80.
19. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409–19.
20. World Health Organization Uppsala Monitoring Centre. Pharmacovigilance: ensuring the safe use of medicines—WHO policy perspectives on medicines. 2004. http://apps.who.int/medicinedocs/fr/d/Js6164e. Accessed 30 Sept 2014.
21. Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 1999;20:109–17.
22. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Introductory guide for standardised MedDRA queries (SMQs). http://www.meddra.org/how-to-use/support-documentation/english. Accessed 30 Sept 2014.
23. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905–8.
24. Thachil J, Callaghan T, Martlew V. Thromboembolic events are not uncommon in patients with immune thrombocytopenia. Br J Haematol. 2010;150:496–7.
25. Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis. 2014;38:306–13.
26. Donnellan E, Kevane B, Bird BRH, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol. 2014;21:134–43.
27. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16:313–8.
28. Stephen M. Introduction. Stephens’ detection and evaluation of adverse drug reactions. 6th ed. Chichester: Wiley; 2014. p. 14.
29. Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, et al. First French experience of ADR reporting by patients after a mass immunization campaign with influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. Drug Saf. 2012;35:845–54.
30. Pages A, Bondon-Guitton E, Montastruc JL, Bagheri H. Undesirable effects related to oral antineoplastic drugs: comparison between patients’ internet narratives and a national pharmacovigilance database. Drug Saf. 2014;37:629–37.
31. Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47:329–31.
32. Weber J. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in inflammation research. New York: Raven; 1984. p. 1–7.
33. Haramburu F, Bégaud B, Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol. 1997;44:299–301.
34. Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc J-L, et al. Trends of reporting of “serious” vs. “non-serious” adverse drug reactions over time: a study in the French pharmacovigilance database. Br J Clin Pharmacol. 2012;74:201–4.